Stonepine Capital Management, LLC

recently disclosed that they own 5% of CTI BioPharma Corp (NASDAQ:CTIC) in a Schedule 13G/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Friday, January 12th. The investor owns 2,150,010 shares of the stock valued at $7,052,033. The reporting parties listed on the disclosure included Stonepine Capital Management, LLC, Stonepine Capital, LP, Jon M Plexico and Timothy P Lynch. The filing is available through the SEC website at this link.

Several other hedge funds and other institutional investors have also modified their holdings of the company. OxFORD Asset Management LLP purchased a new position in CTI BioPharma during the third quarter worth about $164,000. JPMorgan Chase & Co. purchased a new position in CTI BioPharma during the third quarter worth about $272,000. Finally, Stonepine Capital Management LLC purchased a new position in CTI BioPharma during the second quarter worth about $7,561,000. Hedge funds and other institutional investors own 42.81% of the company’s stock.

CTIC has been the topic of several analyst reports. ValuEngine cut shares of CTI BioPharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 11th. Zacks Investment Research cut shares of CTI BioPharma from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd.

Shares of CTI BioPharma Corp (NASDAQ CTIC) opened at $3.28 on Friday. The company has a market cap of $140.94, a PE ratio of -3.18 and a beta of 0.53. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.19 and a quick ratio of 2.17. CTI BioPharma Corp has a 12-month low of $2.45 and a 12-month high of $5.64.

CTI BioPharma (NASDAQ:CTIC) last announced its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. The business had revenue of $1.71 million for the quarter, compared to analyst estimates of $0.30 million. CTI BioPharma had a negative net margin of 96.91% and a negative return on equity of 209.67%. equities analysts forecast that CTI BioPharma Corp will post -1.2 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at

CTI BioPharma Company Profile

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Institutional Ownership by Quarter for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with Analyst Ratings Network's FREE daily email newsletter.